Literature DB >> 24410472

Advances in understanding of bile acid diarrhea.

Michael Camilleri1.   

Abstract

Bile acids (BA) are actively reabsorbed in the terminal ileum by the apical Na(+)-dependent bile salt transporter. This review addresses the epidemiology, pathophysiology, diagnosis and treatment of BA diarrhea (BAD). BAD is typically caused by ileal resection or disease; 25-33% of patients with chronic functional diarrhea or irritable bowel syndrome-diarrhea (IBS-D) have BAD, possibly from deficiency in the ileal hormone, FGF-19, which normally provides feedback inhibition of BA synthesis. Diagnosis of BAD is typically based on reduced BA retention of radiolabeled BA ((75)SeHCAT), increased BA synthesis (serum C4) or increased fecal BA loss. In clinical practice, diagnosis is often based on response to BA sequestrants (e.g., cholestyramine or colesevelam). Diagnostic tests for BA malabsorption (BAM) need to be used more extensively in clinical practice. In the future, farnesoid X receptor agonists that stimulate ileal production of FGF-19 may be alternative treatments of BAD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24410472      PMCID: PMC4211077          DOI: 10.1586/17474124.2014.851599

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  94 in total

Review 1.  Bile acids: short and long term effects in the intestine.

Authors:  Antal Bajor; Per-Göran Gillberg; Hasse Abrahamsson
Journal:  Scand J Gastroenterol       Date:  2010-06       Impact factor: 2.423

Review 2.  Peripheral mechanisms in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

3.  Role of fat maldigestion in pathogenesis of steatorrhea in ileal resection. Fat digestion after two sequential test meals with and without cholestyramine.

Authors:  J R Poley; A F Hofmann
Journal:  Gastroenterology       Date:  1976-07       Impact factor: 22.682

4.  Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride.

Authors:  A F Hofmann; J R Poley
Journal:  Gastroenterology       Date:  1972-05       Impact factor: 22.682

5.  Cholestyramine treatment of diarrhea associated with ileal resection.

Authors:  A F Hofmann; J R Poley
Journal:  N Engl J Med       Date:  1969-08-21       Impact factor: 91.245

Review 6.  Detergent properties of bile salts: correlation with physiological function.

Authors:  A F Hofmann; D M Small
Journal:  Annu Rev Med       Date:  1967       Impact factor: 13.739

7.  Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis.

Authors:  Tiangang Li; Michelle Matozel; Shannon Boehme; Bo Kong; Lisa-Mari Nilsson; Grace Guo; Ewa Ellis; John Y L Chiang
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

8.  Pharmacological inhibition of chenodeoxycholate-induced fluid and mucus secretion and mucosal injury in the rabbit colon.

Authors:  M Camilleri; R Murphy; V S Chadwick
Journal:  Dig Dis Sci       Date:  1982-10       Impact factor: 3.199

9.  Bile acid malabsorption in patients with chronic diarrhoea: clinical value of SeHCAT test.

Authors:  S Wildt; S Nørby Rasmussen; J Lysgård Madsen; J J Rumessen
Journal:  Scand J Gastroenterol       Date:  2003-08       Impact factor: 2.423

Review 10.  Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective.

Authors:  Jonathan D Nolan; Ian M Johnston; Julian R F Walters
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-01       Impact factor: 3.869

View more
  24 in total

Review 1.  Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.

Authors:  Nelson Valentin; Andres Acosta; Michael Camilleri
Journal:  Expert Opin Investig Drugs       Date:  2015-06       Impact factor: 6.206

2.  Eat Your Curry.

Authors:  Purna C Kashyap
Journal:  Cell Host Microbe       Date:  2015-10-14       Impact factor: 21.023

3.  Ileectomy-induced Bile Overaccumulation in Mouse Intestine.

Authors:  Rongli Zhang; Jonathan W Ray; Mukesh K Jain; Shuxin Han
Journal:  J Vis Exp       Date:  2017-08-21       Impact factor: 1.355

Review 4.  Therapeutic targeting of bile acids.

Authors:  Michael Camilleri; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-02       Impact factor: 4.052

5.  Mechanisms of triglyceride metabolism in patients with bile acid diarrhea.

Authors:  Nidhi Midhu Sagar; Michael McFarlane; Chuka Nwokolo; Karna Dev Bardhan; Ramesh Pulendran Arasaradnam
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 6.  Elobixibat and its potential role in chronic idiopathic constipation.

Authors:  Andres Acosta; Michael Camilleri
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

Review 7.  Intestinal transport and metabolism of bile acids.

Authors:  Paul A Dawson; Saul J Karpen
Journal:  J Lipid Res       Date:  2014-09-10       Impact factor: 5.922

8.  Inhibition of CFTR-mediated intestinal chloride secretion as potential therapy for bile acid diarrhea.

Authors:  Tianying Duan; Onur Cil; C Ming Tse; Rafiquel Sarker; Ruxian Lin; Mark Donowitz; Alan S Verkman
Journal:  FASEB J       Date:  2019-07-03       Impact factor: 5.834

9.  Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products.

Authors:  Jiayu Ye; Lauren A E Erland; Sandeep K Gill; Stephanie L Bishop; Andrea Verdugo-Meza; Susan J Murch; Deanna L Gibson
Journal:  Biomolecules       Date:  2021-05-15

10.  Randomized controlled trial of cholestyramine and hydrotalcite to eliminate bile for capsule endoscopy.

Authors:  Chen Hong-Bin; Huang Yue; Huang Chun; Xiao Shu-Ping; Zhang Yue; Li Xiao-Lin
Journal:  Saudi J Gastroenterol       Date:  2016 Mar-Apr       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.